Starting April 21, you’ll be asked to log in or sign up for a free account after viewing 10 content pages each month.
Don’t worry—creating an account is quick and easy, and it comes with added benefits! Once logged in, you’ll not only continue accessing the content you already enjoy, but you’ll also unlock exclusive features like interactive donut plots for variant protein effects and variant impacts across the gene.
Stay tuned for these updates, and thank you for being part of our community!
Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Gene | KIT |
Variant | E562_L576del |
Impact List | deletion |
Protein Effect | gain of function - predicted |
Gene Variant Descriptions | KIT E562_L576del results in the deletion of 15 amino acids in the juxtamembrane domain (exon 11) of the Kit protein from amino acids 562 to 576 (PMID: 16226710). E562_L576del has not been characterized, however similar Kit exon 11 deletions are activating (PMID: 9438854, PMID: 15365079), and therefore, is predicted to lead to a gain of Kit protein function. |
Associated Drug Resistance | |
Category Variants Paths |
KIT mutant KIT act mut KIT exon 11 del KIT E562_L576del KIT mutant KIT exon11 KIT exon 11 del KIT E562_L576del |
Transcript | NM_000222.3 |
gDNA | chr4:g.54727452_54727496del45 |
cDNA | c.1684_1728del45 |
Protein | p.E562_L576del15 |
Source Database | RefSeq |
Genome Build | GRCh38/hg38 |
Transcript | gDNA | cDNA | Protein | Source Database | Genome Build |
---|---|---|---|---|---|
NM_001385290.1 | chr4:g.54727449_54727493del45 | c.1684_1728del45 | p.E562_Q576del15 | RefSeq | GRCh38/hg38 |
NM_001385288.1 | chr4:g.54727461_54727505del45 | c.1684_1728del45 | p.G562_D576del15 | RefSeq | GRCh38/hg38 |
NM_001093772.2 | chr4:g.54727466_54727510del45 | c.1686_1730del45 | p.N562_H576del15 | RefSeq | GRCh38/hg38 |
NM_000222.3 | chr4:g.54727452_54727496del45 | c.1684_1728del45 | p.E562_L576del15 | RefSeq | GRCh38/hg38 |
NM_001385285.1 | chr4:g.54727452_54727496del45 | c.1684_1728del45 | p.E562_L576del15 | RefSeq | GRCh38/hg38 |
NM_001385286.1 | chr4:g.54727466_54727510del45 | c.1686_1730del45 | p.N562_H576del15 | RefSeq | GRCh38/hg38 |
NM_000222.2 | chr4:g.54727452_54727496del45 | c.1684_1728del45 | p.E562_L576del | RefSeq | GRCh38/hg38 |
NM_001385292.1 | chr4:g.54727461_54727505del45 | c.1684_1728del45 | p.G562_D576del15 | RefSeq | GRCh38/hg38 |
NM_001385284.1 | chr4:g.54727449_54727493del45 | c.1684_1728del45 | p.E562_Q576del15 | RefSeq | GRCh38/hg38 |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
KIT E562_L576del | gastrointestinal stromal tumor | predicted - sensitive | Binimetinib + Imatinib | Case Reports/Case Series | Actionable | In a Phase II trial, Gleevec (imatinib) and Mektovi (binimetinib) combination treatment resulted in an 80% pathological response and 23% RECIST response in a patient with a small bowel gastrointestinal stromal tumor harboring KIT E562_L576del (PMID: 35041493; NCT01991379). | 35041493 |